As of November 10, 2026, Perspective Therapeutics, Inc. is a publicly traded company (NYSE: CATX). The largest holder reporting an active stake on Schedule 13D is Lantheus Holdings, Inc., at 7.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Commodore Capital (9.9%), BlackRock (6.8%), Millennium (5.5%) (Schedule 13D/A, September 23, 2026).
Is this your company?
About to sign with, pay or invest in Perspective Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Perspective Therapeutics, Inc. a real, registered company?
- Perspective Therapeutics, Inc. files with the SEC under CIK 728387 (its SEC filings).
- Its shares are listed under the ticker CATX on NYSE (SEC company record).
- Incorporated in Delaware; business address in Seattle, Washington, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Perspective Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Lantheus Holdings, Inc. (filed 2026-09-23).
Who are Perspective Therapeutics, Inc.'s owners and officers?
Perspective Therapeutics, Inc.: incorporated in Delaware; business address in Seattle, Washington; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-09-23).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-03-18)
- : Director (Form D, 2024-03-18)
- : Director (Form D, 2024-03-18)
- : Director (Form D, 2024-03-18)
- : Director (Form D, 2024-03-18)
- : Executive Officer (Form D, 2024-03-18)
- : Executive Officer (Form D, 2024-03-18)
- : Executive Officer (Form D, 2024-03-18)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-09-23 | Lantheus Holdings, Inc. | 7.7% |
| Schedule 13D/A, 2026-09-04 | Lantheus Holdings, Inc. | 10% |
| Schedule 13G/A, 2026-08-13 | Millennium Management LLC | 5.5% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.3% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 6.8% |
| Schedule 13G, 2026-07-20 | Millennium Management LLC | 5.3% |
| Schedule 13G, 2026-06-30 | Millennium Management LLC | 4.3% |
| Schedule 13G/A, 2026-05-12 | Morgan Stanley | 2.6% |
| Schedule 13G/A, 2026-04-27 | Blackrock, Inc. | 4.6% |
| Schedule 13G, 2026-03-10 | Avidity Partners Management LP | 5.3% |
| Schedule 13G, 2026-02-12 | Morgan Stanley | 6% |
| Schedule 13G, 2026-02-09 | Commodore Capital LP | 9.9% |
Questions about who owns Perspective Therapeutics, Inc.
Who owns Perspective Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Perspective Therapeutics, Inc.: Commodore Capital LP (9.9%, Schedule 13G, filed 2026-02-09), Lantheus Holdings, Inc. (7.7%, Schedule 13D/A, filed 2026-09-23), Blackrock, Inc. (6.8%, Schedule 13G, filed 2026-07-29), Millennium Management LLC (5.5%, Schedule 13G/A, filed 2026-08-13) and State Street Corporation (5.3%, Schedule 13G, filed 2026-08-07); 1 more is listed above.
Who are the largest shareholders of Perspective Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Perspective Therapeutics, Inc. on this page are Commodore Capital LP (9.9%), Lantheus Holdings, Inc. (7.7%) and Blackrock, Inc. (6.8%).
When did Commodore Capital LP buy into Perspective Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G, filed 2026-02-09, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Perspective Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Perspective Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Perspective Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Perspective Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Lantheus Holdings, Inc., a 10% owner: 11,273,364 shares (9.3% of shares outstanding), on a joint filing (Form 4, 2026-09-08).
- Lantheus Alpha Therapy, LLC, a 10% owner: 11,273,364 shares (9.3% of shares outstanding), on a joint filing (Form 4, 2026-09-08).
- , a director: 188,267 shares (0.16% of shares outstanding), 4,807 held directly and 183,460 indirectly (Form 4, 2025-04-01).
- , a director: 118,846 shares (0.10% of shares outstanding), 108,982 held directly and 9,864 indirectly (Form 4, 2025-11-14).
- Johan (Thijs) Spoor, the chief executive and a director: 87,683 shares (0.07% of shares outstanding), 59,383 held directly and 28,300 indirectly (Form 4, 2025-04-01).
Shares outstanding: 120,758,815 as of 2026-11-04, from the company's latest SEC cover page.
How much has Perspective Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-03-18 | $87.41M | $87.41M |
| Form D, 2024-01-22 | $20.85M | $20.85M |
| Form D, 2023-02-21 | $54.62M | $54.62M |
Keep reading
More on Perspective Therapeutics, Inc. and the records around it.
Perspective Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
Companies that share a holder
- Lantheus Holdings, Inc. also filed stake reports on 1 other company: Radiopharm Theranostics Limited (Sep 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Scynexis, Inc. (Feb 2026)
- Qatar Investment Authority also filed stake reports on 11 other companies: Aspen Neuroscience, Inc. (Nov 2026), Global Business Travel Group, Inc. (Sep 2026), Nanobiotix SA (Jul 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/perspective-therapeutics